Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

L. Hare, GAA. Burke, SD. Turner

. 2021 ; 13 (23) : . [pub] 20211129

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22001185

Non-Hodgkin lymphoma (NHL) is the third most common malignancy diagnosed in children. The vast majority of paediatric NHL are either Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma (LL). Multi-agent chemotherapy is used to treat all of these types of NHL, and survival is over 90% but the chemotherapy regimens are intensive, and outcomes are generally poor if relapse occurs. Therefore, targeted therapies are of interest as potential solutions to these problems. However, the major problem with all targeted agents is the development of resistance. Mechanisms of resistance are not well understood, but increased knowledge will facilitate optimal management strategies through improving our understanding of when to select each targeted agent, and when a combinatorial approach may be helpful. This review summarises currently available knowledge regarding resistance to targeted therapies used in paediatric anaplastic lymphoma kinase (ALK)-positive ALCL. Specifically, we outline where gaps in knowledge exist, and further investigation is required in order to find a solution to the clinical problem of drug resistance in ALCL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001185
003      
CZ-PrNML
005      
20220112153524.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13236003 $2 doi
035    __
$a (PubMed)34885113
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hare, Lucy $u Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK $u Department of Paediatric Oncology and Haematology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
245    10
$a Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL / $c L. Hare, GAA. Burke, SD. Turner
520    9_
$a Non-Hodgkin lymphoma (NHL) is the third most common malignancy diagnosed in children. The vast majority of paediatric NHL are either Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma (LL). Multi-agent chemotherapy is used to treat all of these types of NHL, and survival is over 90% but the chemotherapy regimens are intensive, and outcomes are generally poor if relapse occurs. Therefore, targeted therapies are of interest as potential solutions to these problems. However, the major problem with all targeted agents is the development of resistance. Mechanisms of resistance are not well understood, but increased knowledge will facilitate optimal management strategies through improving our understanding of when to select each targeted agent, and when a combinatorial approach may be helpful. This review summarises currently available knowledge regarding resistance to targeted therapies used in paediatric anaplastic lymphoma kinase (ALK)-positive ALCL. Specifically, we outline where gaps in knowledge exist, and further investigation is required in order to find a solution to the clinical problem of drug resistance in ALCL.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Burke, G A Amos $u Department of Paediatric Oncology and Haematology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
700    1_
$a Turner, Suzanne D $u Department of Pathology, University of Cambridge, Cambridge CB2 0QQ, UK $u CEITEC, Masaryk University, 62500 Brno, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 23 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34885113 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153520 $b ABA008
999    __
$a ind $b bmc $g 1745394 $s 1152332
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 23 $e 20211129 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20220107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace